Champlain Bio develops next‑generation, disease‑modifying therapies that rebalance the immune system by targeting underlying mechanisms such as autoantibody production and protein aggregation. Their lead program uses a proprietary monoclonal antibody to intervene at the root cause of autoimmune diseases, and preclinical studies have shown strong efficacy in models of immune dysregulation. The company aims to provide durable, long‑term outcomes for patients with high‑risk, relapse‑prone conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with high‑risk autoimmune diseases often experience relapses and lack therapies that modify the underlying immune dysfunction, leading to persistent symptoms and progressive organ damage.
Solution
Champlain Bio is developing next‑generation, disease‑modifying therapies that rebalance the immune system by targeting core mechanisms such as autoantibody production and protein aggregation. Its lead program employs a proprietary monoclonal antibody designed to provide long‑term immune modulation rather than temporary symptom relief. Preclinical studies have demonstrated strong efficacy, supporting the potential to improve outcomes for patients who currently have no effective treatment options. The company’s approach focuses on durable, real‑world impact through precise targeting of the root causes of autoimmune pathology.
Target Audience
Primary customers are pharmaceutical partners and clinical development teams focused on high‑risk autoimmune disease populations lacking effective disease‑modifying treatments.
Features
- Proprietary monoclonal antibody platform engineered for sustained immune modulation
- Targets autoantibody production pathways to reduce pathogenic antibody levels
- Addresses protein aggregation mechanisms that contribute to disease progression
- Designed as a disease‑modifying therapy rather than a symptomatic treatment
- Preclinical data showing significant efficacy in relevant autoimmune models
- Scalable biologic manufacturing process for future clinical development